Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease

L. O’Donoghue, Michelle; P. Giugliano, Robert; D. Wiviott, Stephen; Atar, Dan; Keech, Anthony; Kuder, Julia; Im, KyungAh; A. Murphy, Sabina; H. Flores‐Arredondo, Jose; Antonio G. López, J.; Elliott‐Davey, Mary; Wang, Bei; Laura Monsalvo, Maria; Abbasi, Siddique; S. Sabatine, Marc

doi:10.1161/circulationaha.122.061620

Public

Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease

Published in Circulation • Aug 29, 2022

Authors:

Michelle L. O’Donoghue

Robert P. Giugliano

Stephen D. Wiviott

Abstract

Background: In FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk), the proprotein convertase subtilisin-kexin type 9 inhibitor evolocumab reduced low-density lipoprotein cholesterol (LDL-C) and risk of cardiovascular events and was safe and well t...

Subject

Medicine

Evolocumab

Atherosclerotic cardiovascular disease

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!